1US Renal Data System. USRDS 2000 Annual Data Report.Bethesda,Md: National Institute of Diabetes and Digestive and Kidney Diseases, 2000. 被引量：1
2Lewis EJ, Hunsicker LG, Bain RP,et al. The effect of angiotensinconverting-enzyme inhibition on diabetic nephropathy[J]. N Engl J Med. 1993,329:1456-1462. 被引量：1
3Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy[J]. N Engl J Med. 2001,345:861-869. 被引量：1
4Lewis E J, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes[J]. N Engl J Med. 2001,345: 851-860. 被引量：1
5Hou FF, Zhang X, Zhang GH, et al. Efficacy and safety of benazepril for advanced chronic renal insufficiency [J]. N Engt J Med. 2006,354:131-140. 被引量：1
6Sharma K, Jin YL, Guo J, et al. Neutralization of TGFβ1 antibody attenuates kidney hypertrophy and the enchanced extracellular matrix gene expression in STZ-induced diabetic mice [J]. Diabetes,1996,45:522-530. 被引量：1
9United Kingdom Prospective Diabetes Study. A multicenter study. Ⅲ.Prevalence of hypertension and hypotension therapy in patients with newly diagnosed diabetes[J]. Hypertension,1985,7(Suppl 2): Ⅱ8-Ⅱ13. 被引量：1
10Ravid M, Savin H, Jutrin Let al. Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type Ⅱ diabetic patients [J]. Ann Intern Med, 1993, 118:577-581. 被引量：1
